Urocortin-2 induces vasorelaxation of coronary arteries isolated from patients with heart failure

Clinical and Experimental Pharmacology and Physiology

Volumn 38, Issue 1, 2011, Pages 71-76

  Smani, Tarik ^a   Calderon, Eva ^a   Rodriguez Moyano, Maria ^a   Dominguez Rodriguez, Alejandro ^a   Diaz, Ignacio ^a   Ordóñez, Antonio ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

CAMP; Endothelium; Heart failure; Human coronary artery; Protein kinase A; Urocortin 2

Indexed keywords

ADENYLATE CYCLASE; CORTICOTROPIN RELEASING FACTOR; CYCLIC AMP DEPENDENT PROTEIN KINASE; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; UROCORTIN II;

ADULT; ARTICLE; BLOOD VESSEL TONE; CLINICAL ARTICLE; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; CORONARY ARTERY DILATATION; HEART FAILURE; HEART TRANSPLANTATION; HUMAN; HUMAN TISSUE; PATHOPHYSIOLOGY;

ADENYLATE CYCLASE; ADULT; CORONARY VESSELS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; ENZYME ACTIVATION; HEART FAILURE; HUMANS; ISOTONIC CONTRACTION; MIDDLE AGED; TENSILE STRENGTH; TISSUE AND ORGAN HARVESTING; UROCORTINS; VASODILATION; VASODILATOR AGENTS;

EID: 78650660193     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2010.05466.x     Document Type: Article

References (44)

1. Venkatasubramanian S, Newby DE, Lang NN. Urocortins in heart failure. Biochem. Pharmacol. 2010; 80: 289-96.
2. Vale W, Spiess J, Rivier C, Rivier J. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science 1981; 213: 1394-7.
3. Vaughan J, Donaldson C, Bittencourt J et al. Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature 1995; 378: 287-92.
4. Calderón-Sanchez E, Delgado C, Ruiz-Hurtado G et al. Urocortin induces positive inotropic effect in rat heart. Cardiovasc. Res. 2009; 83: 717-25.
5. Smani T, Calderón-Sanchez E, Gómez-Hurtado N et al. Mechanisms underlying the activation of L-type calcium channels by urocortin in rat ventricular myocytes. Cardiovasc. Res. 2010; 87: 459-66.
6. Lawrence KM, Latchman DS. The urocortins: mechanisms of cardioprotection and therapeutic potential. Mini Rev. Med. Chem. 2006; 6: 1119-26.
7. Reyes TM, Lewis K, Perrin MH et al. Urocortin II. A member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by Type 2 CRF receptors. Proc. Natl Acad. Sci. USA 2001; 98: 2843-8.
8. Baigent SM, Lowry PJ. mRNA expression profiles for corticotrophin releasing factor (CRF), urocortin, CRF receptors and CRF-binding protein in peripheral rat tissues. J. Mol. Endocrinol. 2000; 25: 43-52.
9. Lewis K, Li C, Perrin MH et al. Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc. Natl Acad. Sci. USA 2001; 98: 7570-5.
10. Wiley KE, Davenport AP. CRF2 receptors are highly expressed in the human cardiovascular system and their cognate ligands urocortins 2 and 3 are potent vasodilators. Br. J. Pharmacol. 2004; 143: 508-14.
11. Charles CJ, Rademaker MT, Richards AM. Urocortins: putative role in cardiovascular disease. Curr. Med. Chem. Cardiovasc. Hematol. Agents 2004; 2: 43-7.
12. Nishikimi T, Miyata A, Horio T et al. Urocortin, a member of the corticotropin-releasing factor family, in normal and diseased heart. Am. J. Physiol. Heart Circ. Physiol. 2000; 279: H3031-9.
13. Ikeda K, Tojo K, Tokudome G et al. Cardiac expression of urocortin (Ucn) in diseased heart; preliminary results on possible involvement of urocortin in pathophysiology of cardiac diseases. Mol. Cell. Biochem. 2003; 252: 25-32.
14. Rademaker MT, Cameron VA, Charles CJ, Richards AM. Integrated hemodynamic, hormonal, and renal actions of urocortin 2 in normal and paced sheep: Beneficial effects in heart failure. Circulation 2005; 112: 3624-32.
15. Davis ME, Pemberton CJ, Yandle TG et al. Urocortin 2 infusion in healthy humans: Hemodynamic, neurohormonal, and renal responses. J. Am. Coll. Cardiol. 2007; 49: 461-71.
16. Davis ME, Pemberton CJ, Yandle TG et al. Urocortin 2 infusion in human heart failure. Eur. Heart J. 2007; 28: 2589-97.
17. Huang Y, Chan FL, Lau CW et al. Urocortin-induced endothelium-dependent relaxation of rat coronary artery. Role of nitric oxide and K+ channels. Br. J. Pharmacol. 2002; 135: 1467-76.
18. Schilling L, Kanzler C, Schmiedek P, Ehrenreich H. Characterization of the relaxant action of urocortin, a new peptide related to corticotropin-releasing factor in the rat isolated basilar artery. Br. J. Pharmacol. 1998; 125: 1164-71.
19. 2 + sensitivity of contraction in mouse tail arteries is attributable to cAMP-dependent dephosphorylation of MYPT1 and activation of myosin light chain phosphatase. Circ. Res. 2006; 98: 1159-67.
20. 2 and store-operated pathway in urocortin-induced vasodilatation of rat coronary artery. Circ. Res. 2007; 101: 1194-203.
21. Chen ZW, Huang Y, Yang Q, Li X, Wei W, He GW. Urocortin-induced relaxation in the human internal mammary artery. Cardiovasc. Res. 2005; 65: 913-20.
22. Leitch IM, Boura AL, Botti C, Read MA, Walters WA, Smith R. Vasodilator actions of urocortin and related peptides in the human perfused placenta in vitro. J. Clin. Endocrinol. Metab. 1998; 83: 4510-13.
23. Sanz E, Monge L, Fernandez N et al. Relaxation by urocortin of human saphenous veins. Br. J. Pharmacol. 2002; 136: 90-4.
24. 2+ channel activity by hypoxia in human and porcine coronary myocytes. Cardiovasc. Res. 2002; 53: 97-104.
25. 2+ release in mammalian coronary arteries. Cardiovasc. Res. 2009; 82: 115-24.
26. Dautzenberg FM, Hauger RL. The CRF peptide family and their receptors: Yet more partners discovered. Trends Pharmacol. Sci. 2002; 23: 71-7.
27. Purves GI, Kamishima T, Davies LM, Quayle JM, Dart C. Exchange protein activated by cAMP (Epac) mediates cAMP-dependent but protein kinase A-insensitive modulation of vascular ATP-sensitive potassium channels. J. Physiol. 2009; 587: 3639-50.
28. Rose'Meyer RB. Adenosine receptor interactions alter cardiac contractility in rat heart. Clin. Exp. Pharmacol. Physiol. 2010; 37: 46-50.
29. Murray KJ. Cyclic AMP and mechanisms of vasodilation. Pharmacol. Ther. 1990; 47: 329-45.
30. Taylor DO, Stehlik J, Edwards LB et al. Registry of the International Society for Heart and Lung Transplantation: Twenty-sixth Official Adult Heart Transplant Report: 2009. J. Heart Lung Transplant. 2009; 28: 1007-22.
31. + channels in endothelium-independent relaxation by urocortin in the rat coronary artery. Cardiovasc. Res. 2003; 57: 824-33.
32. Terui K, Higashiyama A, Horiba N, Furukawa KI, Motomura S, Suda T. Coronary vasodilation and positive inotropism by urocortin in the isolated rat heart. J. Endocrinol. 2001; 169: 177-83.
33. Wright SP, Doughty RN, Frampton CM, Gamble GD, Yandle TG, Richards AM. Plasma urocortin 1 in human heart failure. Circ. Heart Fail. 2009; 2: 465-71.
34. Gruson D, Ahn SA, Ketelslegers JM, Rousseau MF. Circulating levels of stress associated peptide urocortin in heart failure patients. Peptides 2010; 31: 354-6.
35. Davidson SM, Yellon DM. Urocortin. A protective peptide that targets both the myocardium and vasculature. Pharmacol. Rep. 2009; 61: 172-82.
36. Falk E. Pathogenesis of atherosclerosis. J. Am. Coll. Cardiol. 2006; 47: C7-12.
37. Landmesser U, Drexler H. The clinical significance of endothelial dysfunction. Curr. Opin. Cardiol. 2005; 20: 547-51.
38. Bale TL, Hoshijima M, Gu Y et al. The cardiovascular physiologic actions of urocortin II. Acute effects in murine heart failure. Proc. Natl Acad. Sci. USA 2004; 101: 3697-702.
39. Kageyama K, Furukawa K, Miki I, Terui K, Motomura S, Suda T. Vasodilative effects of urocortin II via protein kinase A and a mitogen-activated protein kinase in rat thoracic aorta. J. Cardiovasc. Pharmacol. 2003; 42: 561-5.
40. Feldman AM. Modulation of adrenergic receptors and G-transduction proteins in failing human ventricular myocardium. Circulation 1993; 87(Suppl.): IV-27-34.
41. Nakamura I, Yoshikawa T, Anzai T et al. Presynaptic modulation of the norepinephrine-induced beta-adrenergic receptor desensitization phenomenon in vivo. J. Cardiac Fail. 2000; 6: 350-8.
42. Post SR, Hammond HK, Insel PA. Beta-adrenergic receptors and receptor signaling in heart failure. Annu. Rev. Pharmacol. Toxicol. 1999; 39: 343-60.
43. Lamba S, Abraham WT. Alterations in adrenergic receptor signaling in heart failure. Heart Fail. Rev. 2000; 5: 7-16.
44. Burnett JC. Urocortin: Advancing the neurohumoral hypothesis of heart failure. Circulation 2005; 112: 3544-6.